Company Filing History:
Years Active: 2003-2007
Title: Innovations by Andreas Fisch in Nucleic Acids
Introduction
Andreas Fisch is a notable inventor based in St. Gallen, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acids encoding factor X analogues. With a total of 2 patents, his work has implications for medical and therapeutic applications.
Latest Patents
Fisch's latest patents include innovative nucleic acids that encode factor X analogues with a modified protease cleavage site. The first patent describes nucleic acids that have a modification in the region of the natural Factor Xa activation cleavage site. This modification results in a processing site for a protease that does not naturally cleave in this region of the Factor X sequence. The second patent focuses on factor X analogues that also feature a modification in the same region, providing a processing site for a protease not typically cleaving in this area. These advancements could lead to new therapeutic strategies in coagulation disorders.
Career Highlights
Andreas Fisch is currently associated with Baxter Aktiengesellschaft, a leading global healthcare company. His work at Baxter has allowed him to explore and develop innovative solutions in the field of biotechnology. His contributions have been instrumental in advancing the understanding and application of factor X analogues.
Collaborations
Fisch has collaborated with notable colleagues, including Michele Himmelspach and Uwe Schlokat. These partnerships have fostered a collaborative environment that enhances the research and development of innovative biotechnological solutions.
Conclusion
Andreas Fisch's work in the field of nucleic acids and factor X analogues showcases his innovative spirit and dedication to advancing biotechnology. His patents reflect significant advancements that could have a lasting impact on medical therapies.